Open AccessThe multivariate analysis of results of bedaquiline use in the therapy of MDR/XDR pulmonary tuberculosis
Author(s) -
N. V. Stavitskaya,
Irina Felker,
Е. Н. Жукова,
А. I. Tlif,
N. P. Doktorovа,
D.А. Kudlаy
Publication year - 2020
Publication title -
tuberkulez i bolezni lëgkih/tuberkulëz i bolezni lëgkih
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.226
H-Index - 12
eISSN - 2542-1506
pISSN - 2075-1230
DOI - 10.21292/2075-1230-2020-98-7-56-62
Subject(s) - bedaquiline , medicine , multivariate analysis , tolerability , regimen , tuberculosis , retrospective cohort study , adverse effect , surgery , mycobacterium tuberculosis , pathology
The objective of the study: to perform the multivariate analysis of treatment outcomes in patients with multiple/extensive drug resistant tuberculosis (MDR/XDR TB), including those with HIV infection, whose chemotherapy regimens included bedaquiline. Subjects and methods: 70 patients with MDR/XDR TB were enrolled in the retrospective two-center study, the multivariate analysis of treatment outcomes with bedaquiline-containing regimen was carried out. Results: the performed multivariate analysis demonstrated high efficacy and good tolerability of bedaquiline-containing regimens for MDR/XDR TB treatment even despite the continuous ineffective treatment of patients in the past. The prolonged intake of bedaquiline for more than 24 weeks was not associated with a high level of adverse reactions. It was found that the use of cycloserine/terizidone made a significant contribution to the favorable outcome of chemotherapy. The factors associated with the most unfavorable treatment outcomes were the following: age above 60 years, concurrent chronic obstructive pulmonary disease, alcohol and/or drug addiction, and smoking.